Updated 2026-10-09
Undervalued Pharma Stocks: Fair Value vs Price
11 pharma stocks ranked by upside to SageNoodle's fair value estimate; 1 rated undervalued as of 2026-10-09. Price refreshed through the trading day.
| Company | Price | Fair value | Upside | Verdict |
|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | USD 59.69 | USD 75.60 | +26.7% | Undervalued |
| Novo Nordisk A S (NVO) | USD 38.43 | USD 44.01 | +14.5% | Fairly Valued |
| Cigna Group (CI) | USD 282.11 | USD 304.50 | +7.9% | Fairly Valued |
| Abbott Laboratories (ABT) | USD 99.23 | USD 104.00 | +4.8% | Fairly Valued |
| Pfizer (PFE) | USD 28.23 | USD 29.00 | +2.7% | Fairly Valued |
| Merck & Co. (MRK) | USD 146.55 | USD 145.00 | -1.1% | Fairly Valued |
| ELI LILLY & (LLY) | USD 1178.35 | USD 1132.40 | -3.9% | Fairly Valued |
| Gilead Sciences (GILD) | USD 151.26 | USD 137.10 | -9.4% | Fairly Valued |
| AbbVie (ABBV) | USD 276.95 | USD 246.70 | -10.9% | Fairly Valued |
| Amgen (AMGN) | USD 417.10 | USD 370.00 | -11.3% | Fairly Valued |
| Johnson & Johnson (JNJ) | USD 260.71 | USD 216.00 | -17.1% | Overvalued |
Methodology
Fair values come from each company's latest SageNoodle research report (probability-weighted bull, base and bear scenarios); prices refresh through the trading day. Companies whose price and valuation currencies differ are excluded. A fair value is a model output, not investment advice.